Enhabit Inc (NYSE:EHAB)

$ 7.78 0.12 (1.57%) Market Cap: 385.18 Mil Enterprise Value: 952.28 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 22/100

Q3 2024 Enhabit Inc Earnings Call Transcript
Nov 07, 2024

$7.92 (+0.13%)

Earnings
Q2 2024 Enhabit Inc Earnings Call Transcript
Aug 07, 2024

$8.5 (-14.05%)

Earnings
Q4 2023 Enhabit Inc Earnings Call Transcript
Mar 07, 2024

$9.6 (+22.14%)

Earnings
Q3 2023 Enhabit Inc Earnings Call Transcript
Nov 08, 2023

$9.92 (+16.02%)

Earnings
Q2 2023 Enhabit Inc Earnings Call Transcript
Aug 10, 2023

$11.81 (-13.80%)

Earnings
Enhabit Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Q1 2023 Enhabit Inc Earnings Call Transcript
May 10, 2023

$12.33 (-8.73%)

Earnings
Enhabit Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Enhabit Inc at Citi Healthcare & Medtech Conference Transcript
Mar 01, 2023
Q4 2022 Enhabit Inc Earnings Call Transcript
Feb 15, 2023

$15.99 (+12.37%)

Earnings
Enhabit Inc at CJS Securities New Ideas for the New Year Investor Conference (Virtual) Transcript
Jan 11, 2023

Enhabit Inc at Citi Healthcare & Medtech Conference Transcript

Mar 01, 2023 / 05:30PM GMT

Release Date Price: $14.85 (-3.26%)

Transcript

Jason Paul Cassorla

Citigroup Inc., Research Division - Research Analyst

Good afternoon, everyone. Welcome to day one of Citi Healthcare Conference. I'm Jason Cassorla, I cover health care services here at Citi. We're happy to have Enhabit Home Health and Hospice here with us today. Joining us from the company is CEO of Barb Jacobsmeyer; and CFO, Crissy Carlisle. Thank you both for being here today.

Barbara Ann Jacobsmeyer

Enhabit, Inc. - President, CEO & Director

Absolutely.

Questions & Answers

Jason Paul Cassorla

Citigroup Inc., Research Division - Research Analyst

Maybe we'll just start right off the gate on the home health side. From a volume perspective, you've seen this continued decline in fee-for-service Medicare. You highlighted a 4% percent decline in traditional Medicare beneficiaries in your market outright. There's COVID considerations, but maybe just help frame how you're seeing developments on that front if you have opportunity to perhaps take share in fee-for-service Medicare, given

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.